Future Fund LLC Grows Stock Position in Natera, Inc. $NTRA

Future Fund LLC raised its position in Natera, Inc. (NASDAQ:NTRA) by 26.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,881 shares of the medical research company’s stock after buying an additional 3,580 shares during the quarter. Natera comprises about 1.2% of Future Fund LLC’s holdings, making the stock its 28th largest position. Future Fund LLC’s holdings in Natera were worth $3,376,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NTRA. Townsend Asset Management Corp NC ADV bought a new position in shares of Natera during the 1st quarter worth $258,000. Assetmark Inc. raised its stake in Natera by 0.8% in the 1st quarter. Assetmark Inc. now owns 17,546 shares of the medical research company’s stock valued at $3,509,000 after acquiring an additional 145 shares during the period. Jag Capital Management LLC raised its stake in Natera by 5.3% in the 1st quarter. Jag Capital Management LLC now owns 85,091 shares of the medical research company’s stock valued at $17,017,000 after acquiring an additional 4,319 shares during the period. SteelPeak Wealth LLC purchased a new stake in Natera during the first quarter valued at about $473,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Natera by 2.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 463,477 shares of the medical research company’s stock valued at $94,183,000 after purchasing an additional 8,979 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on NTRA. JPMorgan Chase & Co. increased their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Royal Bank Of Canada initiated coverage on shares of Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Finally, BTIG Research set a $275.00 price objective on shares of Natera and gave the company a “buy” rating in a research note on Wednesday, June 24th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.83.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $272.90, for a total value of $818,700.00. Following the completion of the transaction, the insider directly owned 134,643 shares in the company, valued at approximately $36,744,074.70. This trade represents a 2.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 178,872 shares of company stock valued at $39,627,696. Company insiders own 5.05% of the company’s stock.

Natera Stock Up 0.6%

Shares of NASDAQ NTRA opened at $271.39 on Friday. The company has a market cap of $38.87 billion, a P/E ratio of -166.50 and a beta of 1.51. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The business has a 50-day simple moving average of $233.97 and a two-hundred day simple moving average of $220.41.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.